VivoSeq
Other

Tachycardia

26

Pipeline Programs↗

10

Active Trials↗

14

Companies Involved↗

Tachycardia is an emerging landscape with 26 programs across 14 companies. The most active players are AstraZeneca, McGuff Pharmaceuticals, Inc., La Jolla Pharmaceutical Company. 6 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

15/100

Mech. Concentration

21/100

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 1M

McGuff Pharmaceuticals, Inc.

1 program

Phase 1L

La Jolla Pharmaceutical Company

1 program

Phase 1Regeneron logo

Regeneron

1 program

Phase 2U

United BioPharma

1 program

Phase 2W

Watson Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical9

Ropivacaine

Fresenius Kabi Oncology Ltd.

Acetaminophen

Kenvue Brands

Phenylephrine

Exela Pharma Sciences, LLC.

Isoproterenol

Sanofi

Bisoprolol

Teva

Phase 13

Losartan

Organon and Co

Metoprolol Succinate

AstraZeneca

Angiotensin II

La Jolla Pharmaceutical Company

Phase 23

Pyridostigmine

United BioPharma

Iron

Watson Pharmaceuticals

REGN7544

Regeneron

Phase 35

Ivabradine

Amgen

Beta Blocker

Weill Medical College of Cornell University

Esmolol

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Carbidopa

LaTonya J. Hickson

Anti-Arrhythmia Agents

National Heart, Lung, and Blood Institute (NHLBI)

Approved6

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Magnesium Sulfate

Fresenius Kabi Oncology Ltd.

Propranolol

Wyeth-Lederle Vaccines

Landiolol

Aultman Health Foundation

Bisoprolol+pyridostgmine

Seoul National University Hospital

Analysis

Trial Status

28

clinical trials

Completed12 · 43%
Recruiting6 · 21%
Terminated4 · 14%
Not yet recruiting2 · 7%
Unknown status2 · 7%
Active, not recruiting1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

28 trials

Splanchnic Venous Capacitance in Postural Tachycardia Syndrome
Recruiting·VVanderbilt University Medical Center·Phase 2·NCT05375968·50 enrolled
A Study of Pyridostigmine in Postural Tachycardia Syndrome
Recruiting·MMayo Clinic·Phase 2·NCT00409435·50 enrolled
Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
Recruiting·Regeneron logoRegeneron·Phase 2·NCT06593600·81 enrolled
Effect of Atenolol Versus Ivabradine on HRV in TRS Patients on Clozapine With Tachycardia: A Randomised Control Trial.
Recruiting·—·N/A·NCT06505668·40 enrolled
Clinical Evaluation of Arrhythmia Mapping With a Paddle-shaped, High-density, Multi-electrode Mapping Catheter
Recruiting·BBiosense Webster, Inc.·Preclinical·NCT07116525·90 enrolled
A Multicenter Patient Registry for Outcomes of Inappropriate Sinus Tachycardia and Postural Orthostatic Tachycardia Syndrome Treatment
Recruiting·AAtriCure, Inc.·N/A·NCT05107635·500 enrolled
Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)
Active, not recruiting·VVanderbilt University Medical Center·N/A·NCT01000350·40 enrolled
LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery
Not yet recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT07168421·114 enrolled
Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome
Not yet recruiting·SStanford University·N/A·NCT06953661·20 enrolled
Autoimmune Basis for Postural Tachycardia Syndrome
Enrolling by invitation·VVanderbilt University Medical Center·N/A·NCT02725060·58 enrolled
The Renin-Aldosterone Axis in Postural Tachycardia Syndrome
Completed·VVanderbilt University Medical Center·Phase 1·NCT00962949·28 enrolled
Gabapentin Treatment of Postural Tachycardia Syndrome (PoTS)
Completed·MMedstar Health Research Institute·N/A·NCT04345432·10 enrolled
Local Vasoconstriction in Postural Tachycardia Syndrome
Completed·NNew York Medical College·Phase 1·NCT01210430·74 enrolled
Ivabradine Versus Beta-blockers in the Treatment of Inappropriate Sinus Tachycardia
Completed·PPoliclinico Casilino ASL RMB·Phase 3·NCT01657136·20 enrolled
Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)
Completed·VVanderbilt University·N/A·NCT01764711·13 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)